SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-087020
Filing Date
2024-07-29
Accepted
2024-07-26 18:38:24
Documents
11
Period of Report
2024-07-22
Items
Item 2.05: Cost Associated with Exit or Disposal Activities

Document Format Files

Seq Description Document Type Size
1 8-K virx-20240722.htm   iXBRL 8-K 38406
  Complete submission text file 0000950170-24-087020.txt   148463

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT virx-20240722.xsd EX-101.SCH 23862
14 EXTRACTED XBRL INSTANCE DOCUMENT virx-20240722_htm.xml XML 4543
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 241148429
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)